Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

SUNNYVALE, Calif., Feb. 4, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported recent developments and financial results for its fiscal second quarter that ended December 31, 2010.Recent Developments & Highlights

  • Broad Clinical Development Progress for Btk Inhibitor PCI-32765 in B-cell malignanciesPharmacyclics has designed a broad Phase II Program in mantle cell lymphoma, chronic lymphocytic leukemia and diffuse large B-cell lymphoma to inform the Phase III program and regulatory path for PCI-32765. Throughout 2011 we will closely monitor these Phase II studies for confirmatory efficacy and safety signals to establish our regulatory approval strategy in a timely manner.  Please refer to our website on the key trials listed below.-Mantle Cell Lymphoma (MCL) Our Phase IA results in the MCL subset presented at the 2010 American Society of Hematology (ASH) Meeting showed promising activity. We therefore designed a Phase II program which includes 1) an evaluation of PCI-32765 as a single agent in 2 groups (cohorts) of patients with relapsed or refractory disease, those who have failed bortezomib and those who have not yet received bortezomib and 2) a safety study of PCI-32765 in combination with bortezomib. The single agent trial protocol has been developed and we expect to enroll a total of approximately 100 patients, beginning in Q1 of calendar year 2011.-Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL) The Phase IB/II CLL/SLL program is well underway; to date we have dosed 75 patients and plan to complete enrollment by adding another 7 patients during the remainder of Q1 of calendar 2011. We are also evaluating the safety of PCI-32765 in combination with ofatumumab in a Phase IB/II study of patients with relapsed/refractory CLL/SLL. We began enrollment in this study in January of 2011 and expect to dose up
    '/>"/>


  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
    2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
    3. Pharmacyclics, Inc. Rights Offering Oversubscribed
    4. Pharmacyclics Announces Subscription Price for Rights Offering
    5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
    6. Pharmacyclics Files Registration Statement for Rights Offering
    7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
    8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
    9. Pharmacyclics Secures $5.0 Million in Debt Financing
    10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
    11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
    (Date:10/22/2014)... , Oct. 22, 2014 Research and ... Electronics Market by Material, by Application, Geography - Global ... their offering. Organic electronics, also called ... of material science which deals with small conductive molecules ... because small molecules and polymers are carbon based, made ...
    (Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
    Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
    ... Calif., Oct. 5 MAP,Pharmaceuticals, Inc. announced today that ... of common stock at a price of $12.00 per,share. ... addition,MAP Pharmaceuticals has granted the underwriters a 30-day option ... over-allotments, if,any. Merrill Lynch & Co. and Morgan Stanley ...
    ... the, Latest Pre-FDA Multi-Hospital Study using the AppyScore Human Appendicitis ... Blood-based ... AspenBio Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical ... animals and humans, has been,invited to present at the Oppenheimer ...
    ... Oct. 5 Cerimon,Pharmaceuticals, Inc., today announced Paul ... at the 2007 BIO Investor Forum on,Thursday, October ... Palace Hotel in San,Francisco. The presentation will take ... Cerimon Pharmaceuticals Cerimon Pharmaceuticals, Inc. is a ...
    Cached Biology Technology:MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering 2AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference 2AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference 3
    (Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
    (Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
    (Date:10/14/2014)... kind of stem cell that can become either a liver ... to a study published today in the journal Stem ... contradicts current theory on how organs arise from cell layers ... and future treatment for, liver cancer., Thanks to stem cells, ... made up of more than 200 cell types. The original, ...
    Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
    ... Faculty of Medicine & Dentistry at the University of ... neurons. This finding is significant because a specific type ... community as a potential treatment for MS and other ... fellow, Yohannes Haile, both from the Division of Neurology, ...
    ... they comprise most of the Earth,s total biodiversity and play key ... life in and on it, going. One of the global processes ... is currently unbalanced. Humans release more carbon into the atmosphere than ... Mighty Microbes Respond," is a free panel discussion set to take ...
    ... DALLAS May 6, 2011 Cancer researchers at ... of the telomerase enzyme, which is linked to the disease,s ... Cell , demonstrate that telomerase repairs chromosomes in one of ... normally or if the cell is under stress from enzyme ...
    Cached Biology News:Discovery demonstrates potential MS therapy could kill brain cells 2UT Southwestern research reveals how cancer-driving enzyme works 2
    ...
    ...
    Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
    Biology Products: